Due to their hypoimmunogenicity and unique immunosuppressive properties, mesenchymal stem cells （MSCs） are considered one of the most promising adult stem cell types for cell therapy. Although many studies have show...Due to their hypoimmunogenicity and unique immunosuppressive properties, mesenchymal stem cells （MSCs） are considered one of the most promising adult stem cell types for cell therapy. Although many studies have shown that MSCs exert therapeutic effects on several acute and subacute conditions, their long-term effects are not confirmed in chronic diseases. Immunogenicity is a major limitation for cell replacement therapy, and it is not well understood in vivo. We evaluated the immunogenicity of allogeneic MSCs in vivoby transplanting MSCs into normal and diabetic rats viathe tail vein or pancreas and found that MSCs exhibited low immunogenicity in normal recipients and even exerted some immunosuppressive effects in diabetic rats during the initial phase. However, during the later stage in the pancreas group, MSCs expressed insulin and MHC II, eliciting a strong immune response in the pancreas. Simultaneously, the peripheral blood mononuclear cells in the recipients in the pancreas group were activated, and alloantibodies developed in vivo. Conversely, in the tail vein group, MSCs remained immunoprivileged and displayed immunosuppressive effects in vivo. These data indicate that different transplanting mutes and microenvironments can lead to divergent immunogenicity of MSCs.展开更多
基金We thank our colleagues Ya-Ying Zhou, Chun-Yan Deng and Li-Li Ren for their technical assistance. This work was supported by the National Natural Science Foundation of China （No. 81270857）, the Natural Science Foundation of Guangdong （No. $2013010014832）, and the Science and Technology Project of Shenzhen （JCYJ20120618153743791, GJHZ20120618153934353）.
文摘Due to their hypoimmunogenicity and unique immunosuppressive properties, mesenchymal stem cells （MSCs） are considered one of the most promising adult stem cell types for cell therapy. Although many studies have shown that MSCs exert therapeutic effects on several acute and subacute conditions, their long-term effects are not confirmed in chronic diseases. Immunogenicity is a major limitation for cell replacement therapy, and it is not well understood in vivo. We evaluated the immunogenicity of allogeneic MSCs in vivoby transplanting MSCs into normal and diabetic rats viathe tail vein or pancreas and found that MSCs exhibited low immunogenicity in normal recipients and even exerted some immunosuppressive effects in diabetic rats during the initial phase. However, during the later stage in the pancreas group, MSCs expressed insulin and MHC II, eliciting a strong immune response in the pancreas. Simultaneously, the peripheral blood mononuclear cells in the recipients in the pancreas group were activated, and alloantibodies developed in vivo. Conversely, in the tail vein group, MSCs remained immunoprivileged and displayed immunosuppressive effects in vivo. These data indicate that different transplanting mutes and microenvironments can lead to divergent immunogenicity of MSCs.
